Acadian Asset Management
KRYS icon

Acadian Asset Management’s Krystal Biotech KRYS Stock Holding History

Acadian Asset Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,280
Closed -$415K – 1914
2024
Q3 		$415K Buy
+2,280
New +$440K ﹤0.01% 1129
2020
Q1 		– Sell
-5,032
Closed -$279K – 1859
2019
Q4 		$279K Sell
5,032
-7,921
-61% -$389K ﹤0.01% 1212
2019
Q3 		$450K Sell
12,953
-19,737
-60% -$882K ﹤0.01% 1112
2019
Q2 		$1.32M Buy
32,690
+12,953
+66% +$423K 0.01% 733
2019
Q1 		$649K Sell
19,737
-821
-4% -$19.4K ﹤0.01% 1032
2018
Q4 		$427K Hold
20,558
– – ﹤0.01% 944
2018
Q3 		$361K Buy
20,558
+8,356
+68% +$140K ﹤0.01% 956
2018
Q2 		$182K Buy
12,202
+10,331
+552% +$116K ﹤0.01% 1107
2018
Q1 		$19K Buy
+1,871
New +$18.4K ﹤0.01% 1498

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management's KRYS Position: Q4 2024 in Review

Acadian Asset Management sold out of Krystal Biotech (KRYS) in Q4 2024, closing a stake of 2,280 shares — an estimated $415K sold.

Acadian Asset Management first reported a position in KRYS in Q1 2018 and held it in 9 quarters. The position peaked at $1.32M in Q2 2019. 264 funds tracked by Wall St. Rank hold KRYS as of Q4 2024.

  • Acadian Asset Management reported no remaining Krystal Biotech position as of Q4 2024 after selling out during the quarter.
  • Acadian Asset Management sold 2,280 Krystal Biotech shares in Q4 2024, an estimated $415K.
  • Acadian Asset Management first reported a position in Krystal Biotech in Q1 2018 and held it in 9 quarters.
  • Acadian Asset Management's Krystal Biotech position peaked at $1.32M in Q2 2019.
  • 264 funds tracked by Wall St. Rank held Krystal Biotech as of Q4 2024.

Based on Acadian Asset Management's 13F filing for Q4 2024, filed 11 Feb 2025.